- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Maria Manley Discusses the Consequences of Brexit for the Pharmaceutical Industry
Maria Manley, LLM, a life sciences expert and London-based partner with Sidley Austin, provides a deep-dive look at the complexities of Brexit and how it is likely to challenge the biologics industry.
In an interview with The Center for Biosimilars®, Maria Manley, LLM, a London-based partner with Sidley Austin, explored the complex challenges that Brexit, which marked the United Kingdom’s official exit from the European Union, has presented regulators and the biopharmaceutical industry.
In preparation, pharmaceutical companies have had to ensure that they were properly registered and domiciled so that they could continue doing business in the United Kingdom and Europe.
The United Kingdom and the European Union established a free trade agreement without tariffs and quotas. However, border checks and product movement present problems in Northern Ireland, which is a part of the United Kingdom but is still allowed to follow some EU rules. Manley said there are 2 sets of litigation applying to these jurisdictions, which add to the complexities of Brexit.
On the upside, the United Kingdom has agreed to acknowledge temporarily the marketing authorizations for pharmaceutical drugs that were previously approved in the European Union, ensuring that any impacts on drug supply are minimal.
Some of the regulatory changes for the biologics industry includes an end to animal toxicology studies. Further, comparative efficacy studies will be required only if the United Kingdom’s Medicines and Health products Regulatory Agency deems that there is a sufficient reason.
A new approval pathway for biologics was designed with the intention of simplifying the current system and accelerating the process to get innovative medicines on the market. Manley said that the United Kingdom may be willing to accept real world evidence in support of product approval applications.
Additionally, Manley discussed the “rolling review” feature added to the United Kingdom’s medicines approval process, which was created to enable applications to move through regulatory review quickly. This review format will apply to novel biologics, including biosimilars.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Revolutionizing Biopharmaceuticals: The EU's Biosimilar Success and Remaining Challenges
October 16th 2024The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, lowering costs, and increasing adoption; however, there remains a need for more education, real-world evidence, and efforts to address challenges to enhance patient access and affordability.
